Specific tumour localisation using monoclonal antibodies (MAbs) to tumour-associated antigens has shown to be successful in a variety of malignancies. Immunoscintigraphic detection of ovarian cancer lesions in patients has been performed mostly with radiolabelled MAbs HMFG1 and HMFG2 (Taylor-Papadimitriou et al., 1981; Rainsbury et al., 1983) and with MAb OC125 (Bast et al., 1981) . Another MAb, designated as OV-TL 3, has recently been shown to have good diagnostic accuracy in ovarian cancer Buist et al., 1992) . At present, it is not known which MAb is most useful for tumour localisation in ovarian cancer patients. Recently, we have characterised MAb 139H2 for its reactivity pattern in various types of ovarian tumours (Molthoff et al., 1991a) . MAb 139H2 was found to react better than either MAbs HMFG1 and HMFG2, which are all MAbs directed against the same antigen, episialin. Therefore, we further analysed the in vivo characteristics of MAb 139H2 after radiolabelling and demonstrated specific tumour localisation (Molthoff et al., 1991b) . Several variables have been described which may be important for successful tumour localisation. Among them are the specificity, the affinity, the origin and the size of the MAb, the localisation and the number of antigenic determinants on the tumour cells, the possible heterogeneity in antigen expression and the release of the antigen into the circulation. For different MAbs, most of these variables can be analysed in the laboratory before selecting the optimal antibody for diagnostic use in patients. For that purpose, human tumour cell lines and human tumour xenografts are accepted tools, because of the presence of a series of characteristics relevant for immunological studies. In the present study, we compared the binding characteristics of MAb 139H2 with those of MAbs OC125 and OV-TL 3 in order to assess the potential clinical utility of MAb 139H2. For the 3 MAbs, specificity was determined in vitro as well as in nude mice bearing s.c. human ovarian cancer xenografts (OVCAR-3). Furthermore, we compared the differences between whole IgG and F(ab')2 fragments of the 3 MAbs, particularly with respect to pharmacokinetics, biodistribution and dosimetry in tumour-bearing mice.
Materials and methods
Monoclonal antibodies Some characteristics of the MAbs OC125, OV-TL 3 and 139H2, all of the IgGI isotype, are presented in Table I . MAb OC125 reacts with the cell-surface glycoprotein CA125 present on > 80% of the non-mucinous ovarian cancer subtypes (Bast et al., 1981) . MAb OV-TL 3 recognises a cell surface antigenic determinant OA3, detectable on most ovarian carcinomas (Poels et al., 1986) . MAb 139H2 binds to a protein determinant of episialin, also designated as or CA 15-3 (Hilkens et al., 1989) . The majority of ovarian carcinomas express episialin. The MAbs 2C7 and A2C6, used as control antibodies, are also of the IgGI isotype. MAb 2C7 reacts with human a-glucocerebrosidase (Barneveld et al., 1983) and MAb A2C6 reacts with the hepatitis B surface antigen (Zurawski et al., 1983) . Purified IgG of MAbs OC125 and OV-TL 3 was kindly provided by Dr S.O. Warnaar (Centocor Inc., Leiden, The Netherlands). Purified MAb 2C7 was kindly provided by Dr J.M. Tager (University of Amsterdam, The Netherlands). Ascitic fluid containing MAb 139H2 was kindly provided by Dr J. Hilkens (Netherlands Cancer Institute, Amsterdam) . Purification of this antibody was performed by affinity chromatography using Affi-Gel (Molthoff et al., 1991a) .
Radiolabelling of antibodies andfragments
Whole antibodies and fragments were labelled with either 1251I
or '3lI by the one-vial iodogen method (Haisma et al., 1986 (Table II) . 1, 3, 6, 15, 24, 48, 72 and 168 h after injection. For each time point three mice were used. Blood was collected from mice under ether anaesthesia. Thereafter, normal tissues and tumours were dissected, rinsed in saline and dried to minimise blood residues.
Blood and all tissues were weighed and the radioactivity was measured in a two-channel gamma counter with automatic correction for spillover of both radionuclides in the channels. To correct for radioactive decay, a standard solution of the injected material was prepared and counted simultaneously with the tissues at each day studied. The uptake of antibody was expressed as the percentage of injected dose per gram. The proportion of radioactivity associated with protein in serum was determined by precipitation with 10% TCA. Immune complex formation was analysed using gel filtration Superose-6 or Superose-12 FPLC chromatography.
Radiation dose measurements and calculations The approximate radiation doses to various tissues were derived from the uptake data of the conjugate in each tissue assuming uniform distribution of the radionuclide within the organs. The absorbed dose was then calculated using the trapezoid integration method for the area under the curve (AUC) (Badger et al., 1985) . These doses were expressed in cGy by multiplying the integrated tLCi h g-' by the g.cGy ytCi-'h-' factor for '"'I published by the Medical Internal Radiation Dose committee (Dillman, 1969 A Scatchard analysis was performed with the radiolabelled MAbs on OVCAR-3 cells. The avidity, calculated as apparent affinity constants, for MAbs OC125, OV-TL 3 and 139H2 were lx 109M-1, lx 109M-1 and lx 108M-1, respectively (Table I ). The number of antigenic sites per OVCAR-3 cell for these MAbs was in the range of 1 x 106 to 7 x 106 per cell. Since F(ab')2 fragments of MAb 2C7 could not be made, tumour-bearing mice were injected with MAbs as F(ab')2 fragments with the combination of '3'I-MAb OV-TL 3 plus '25I-MAb OC125 or with '3iI-MAb A2C6 plus 251I-MAb 139H2. Figure 1 shows the pharmacokinetics of the radiolabelled IgGs and F(ab')2 fragments in the blood. The half-lives of MAbs OC125, OV-TL3 and 139H2 were approximately 50 h for IgG and 6 h for F(ab')2 fragments. A similar clearance pattern was observed for the control MAbs. The amount of free iodine in the serum, measured at each time point was < 10%. Serum radioactivity profiles corresponded to that of respectively IgG and F(ab')2 fragments and no immune complexes were observed in the serum (not shown). Figure 2 shows the uptake of the radiolabelled MAbs as IgG and F(ab')2 over a time period of 7 days in the OVCAR-3 tumours. The maximum % of the injected dose g-' in tumour tissue for MAbs OC125, OV-TL 3 and 139H2 as IgG was 8.5%, 17.7% and 11.1%, respectively. This level was reached 3 days after injection and the antibodies cleared slowly from the tumour with half-lifes of >5 days. In contrast, the maximum % injected dose g-' for the control MAb was 2.5% and no retention was observed. For the F(ab')2 fragments, the maximum % of the injected dose g-' in tumour tissue for MAbs OC125, OV-TL 3 and 139H2 was 5.2%, 10.0% and 5.5%, respectively. This level was reached 6 to 15 h after injection. After that, no retention of the fragnents in the tumour was observed. The respective F(ab')2 fragments cleared from the tumour with half-lives of 13 h, 33 h and 30 h, respectively. F(ab')2 fragments of MAb A2C6 reached a maximum of 1.9% of the injected dose g-' tumour without retention. Results for IgG and fragments from the biodistribution experiments in OVCAR-3 bearing mice are summarised in Table III. For IgG as well as for F(ab')2 fragments of the three MAbs OC125, OV-TL 3 and 139H2, uptake in normal organs was much lower than in tumours. At 72 h after injection, liver uptake for the 3 IgGs was 1.5% of the injected dose g-l. The amount of F(ab')2 fragments in the liver measured 1.8% of the injected dose g' at 15 h after injection. Other tissues showed an equal or lower uptake compared with that in the liver, except for the kidneys with respect to the F(ab')2 fragments. Tumour to non-tumour ratios varied largely between IgG and F(ab')2 fragments (Table IV) . The CA125 antigen is also expressed heterogeneously, but on the entire cell membrane and no correlation has been observed with the differentiation status of the tumour (Zurawski et al., 1988) . The OA3 antigen is known to be homogeneously distributed in tumour tissue and detectable on the cell membrane as well as in the cytoplasm (Poels et al., 1986) . In the OVCAR-3 model, the homogeneous OA3 distribution could be an explanation for the increased tumour uptake of MAb OV-TL 3. Upon comparison of the binding characteristics of the three MAbs, MAb OV-TL 3 would be most favourable for clinical application. However, human tumour models may not always predict the behaviour of a MAb administered to patients. MAb OV-TL 3 was found to react with certain subpopulations of human leucocytes and their progenitors (unpublished data). Cross-reactivity with circulating cells in patients has been described by Dillman et al. (1984) for an anti-CEA MAb, which was associated with serious toxicity. In the immunoscintigraphic study using radiolabelled MAb OV-TL 3 in ovarian cancer patients (Buist et al., 1992) , the binding to white blood cells did not seem to interfere with the imaging results or to cause side effects. Nevertheless, significant binding to non-target cells may pose a major limitation with respect to repeated administration or higher doses of MAbs into patients.
Biodistribution of MAbs andfragments
High tumour to normal tissue ratios are considered to be of advantage for the application of radiolabelled MAbs for the detection of tumour lesions in cancer patients. In our study, we observed higher tumour to non-tumour ratios after administration of radiolabelled F(ab')2 fragments compared with IgG. Other investigators demonstrated improved immunoscintigraphic detection of experimental tumours using radiolabelled fragments (Buchegger et al., 1983; Hansson et al., 1988; Gerretsen et al., 1991) . Thus far, clinical data from radioimmunodetection of cancer confirmed an increase in sensitivity for F(ab')2 fragments compared with intact IgG (Lamki et al., 1990) .
For effective radioimmunotherapy, high radiation doses absorbed in tumour tissue would be necessary. In the OVCAR-3 model, we found iodinated MAbs as IgG to deliver four to six times more radiation to tumours than the F(ab')2 fragnents. Earlier, we have demonstrated that high doses of '31I-labelled MAb 139H2 as IgG can induce complete tumour regressions of particular human ovarian cancer xenografts (Molthoff et al., 1992) . Buchegger et al. (1990) have suggested that repeated injections of high doses of '3II-labelled anti-CEA F(ab')2 result in superior therapeutic effects compared with equitoxic doses of 13"I-labelled IgG. In this respect, F(ab')2 fragments may have an advantage because of the higher tumour to normal tissue ratios and the lower bone marrow toxicity from faster blood clearance. Moreover, smaller fragments of MAbs like F(ab')2 or Fab' show a reduced immunogenicity compared with IgG. We consider the lower absolute uptake in tumour tissue and the short retention time as disadvantages for the use of F(ab')2 fragnents for treatment. Future studies should focus on the precise role of IgG versus F(ab')2 in radioimmunotherapy.
From the three antibodies studied, MAb OV-TL 3 shows the most favourable tumour uptake, but the cross-reactivity with certain white blood cells may hamper its therapeutic use. Of interest, the investigational MAb 139H2 has binding characteristics which appear slightly better than MAb OC-125. MAb 139H2 is known to have a broad reactivity pattern with ovarian adenocarcinomas. Therefore, MAb 1 39H2 should be evaluated for its usefulness in the diagnosis of ovarian cancer patients.
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